ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 201 filers reported holding ACADIA PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 1.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $3,535,919 | +60.2% | 217,595 | +82.3% | 0.00% | 0.0% |
Q1 2024 | $2,206,652 | -42.4% | 119,343 | -2.5% | 0.00% | -50.0% |
Q4 2023 | $3,830,716 | +54.8% | 122,348 | +3.0% | 0.00% | +100.0% |
Q3 2023 | $2,474,606 | +3.8% | 118,743 | -6.2% | 0.00% | 0.0% |
Q2 2023 | $2,382,894 | 0.0% | 126,615 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $2,382,894 | -99.9% | 126,615 | +2.8% | 0.00% | 0.0% |
Q3 2022 | $2,015,570,000 | -76.7% | 123,201 | -80.0% | 0.00% | -80.0% |
Q2 2022 | $8,658,826,000 | -37.5% | 614,537 | +7.4% | 0.01% | -16.7% |
Q1 2022 | $13,862,196,000 | +9.6% | 572,345 | +5.6% | 0.01% | +20.0% |
Q4 2021 | $12,650,117,000 | +64.2% | 541,993 | +16.9% | 0.01% | +66.7% |
Q3 2021 | $7,703,851,000 | -34.9% | 463,808 | -4.4% | 0.00% | -40.0% |
Q2 2021 | $11,827,614,000 | +13.6% | 484,937 | +20.1% | 0.01% | 0.0% |
Q1 2021 | $10,413,525,000 | -66.1% | 403,625 | -29.8% | 0.01% | -64.3% |
Q4 2020 | $30,731,213,000 | +26.3% | 574,845 | -2.5% | 0.01% | +7.7% |
Q3 2020 | $24,326,198,000 | -45.4% | 589,726 | -35.9% | 0.01% | -51.9% |
Q2 2020 | $44,575,630,000 | +36.0% | 919,654 | +18.6% | 0.03% | +12.5% |
Q1 2020 | $32,769,186,000 | -11.0% | 775,602 | -9.9% | 0.02% | +4.3% |
Q4 2019 | $36,824,896,000 | +817.6% | 860,797 | +672.0% | 0.02% | +666.7% |
Q3 2019 | $4,013,208,000 | +43.6% | 111,509 | +6.6% | 0.00% | +50.0% |
Q2 2019 | $2,795,076,000 | +10.4% | 104,567 | +10.9% | 0.00% | 0.0% |
Q1 2019 | $2,531,794,000 | +92.8% | 94,294 | +16.1% | 0.00% | +100.0% |
Q4 2018 | $1,312,923,000 | -7.7% | 81,195 | +18.4% | 0.00% | 0.0% |
Q3 2018 | $1,423,057,000 | +36.0% | 68,548 | +0.0% | 0.00% | 0.0% |
Q2 2018 | $1,046,439,000 | -92.4% | 68,529 | -88.8% | 0.00% | -90.9% |
Q1 2018 | $13,743,686,000 | -48.7% | 611,646 | -31.2% | 0.01% | -52.2% |
Q4 2017 | $26,779,111,000 | -9.5% | 889,376 | +13.2% | 0.02% | -14.8% |
Q3 2017 | $29,600,821,000 | +37.6% | 785,793 | +1.8% | 0.03% | +28.6% |
Q2 2017 | $21,519,003,000 | -11.9% | 771,567 | +8.6% | 0.02% | -16.0% |
Q1 2017 | $24,422,417,000 | +122398.0% | 710,367 | +2.8% | 0.02% | +13.6% |
Q4 2016 | $19,937,000 | -12.6% | 691,343 | -3.6% | 0.02% | -12.0% |
Q3 2016 | $22,805,000 | +6.9% | 716,936 | +9.1% | 0.02% | +4.2% |
Q2 2016 | $21,331,000 | -5.3% | 657,156 | -18.4% | 0.02% | -7.7% |
Q1 2016 | $22,522,000 | -17.6% | 805,484 | +5.1% | 0.03% | -16.1% |
Q4 2015 | $27,317,000 | +8.2% | 766,260 | +0.4% | 0.03% | +10.7% |
Q3 2015 | $25,244,000 | -28.7% | 763,375 | -9.7% | 0.03% | -17.6% |
Q2 2015 | $35,396,000 | +59.5% | 845,177 | +24.1% | 0.03% | +61.9% |
Q1 2015 | $22,198,000 | +2.9% | 681,131 | +0.2% | 0.02% | 0.0% |
Q4 2014 | $21,578,000 | +2580.5% | 679,631 | +1989.2% | 0.02% | +2000.0% |
Q3 2014 | $805,000 | +9.8% | 32,531 | +0.3% | 0.00% | 0.0% |
Q2 2014 | $733,000 | -7.1% | 32,431 | 0.0% | 0.00% | 0.0% |
Q1 2014 | $789,000 | +56.2% | 32,431 | +60.5% | 0.00% | 0.0% |
Q4 2013 | $505,000 | -38.7% | 20,200 | -32.7% | 0.00% | 0.0% |
Q3 2013 | $824,000 | +150.5% | 30,000 | +65.7% | 0.00% | – |
Q2 2013 | $329,000 | – | 18,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 647,833 | $26,723,000 | 11.32% |
GREAT POINT PARTNERS LLC | 1,921,563 | $79,264,000 | 7.13% |
Baker Brothers Advisors | 41,904,586 | $1,728,564,000 | 6.91% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 486,000 | $20,048,000 | 6.47% |
Palo Alto Investors LP | 1,832,300 | $75,582,000 | 4.15% |
Birchview Capital, LP | 204,000 | $8,416,000 | 2.81% |
SECTORAL ASSET MANAGEMENT INC | 556,514 | $22,956,000 | 1.97% |
Rock Springs Capital Management LP | 1,573,200 | $64,895,000 | 1.65% |
Riggs Asset Managment Co. Inc. | 17,470 | $2,025,000 | 0.85% |
PFM Health Sciences, LP | 421,087 | $17,370,000 | 0.80% |